Abstract: A compound comprising an oligomer formed from a biocompatible multifunctional carboxylic acid comprising a hydroxyl group and at least one carboxylic acid, an polyol (e.g., an aliphatic diol), and a linker. One or more conductive oligomers (e.g., polyanilines) are covalently bonded to the oligomer. The compounds can have various forms (e.g., articles of manufacture, films, scaffolds, and the like). The compounds have various uses. For example, the compounds are used in photoacoustic imaging methods.

Abstract: Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X3(HCA)2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.

Abstract: The present application relates to strontium L-lactate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable strontium to mammals and treating or preventing symptoms of bone and/or cartilage disorders.

Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Abstract: A layer of a metal selected from titanium, niobium, tungsten, molybdenum, ruthenium, rhodium, arsenic, aluminum and gallium, an oxide of the metal, a nitride of the metal, silicon nitride, hafnium nitride, tantalum nitride, or an alloy of these metals, the layer being provided on an underlying base material selected from glass, silicon, copper and nickel, is selectively etched with an alkaline etching solution containing a predefined complexing agent.

Abstract: The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.

Abstract: Compositions containing calcium citrate malate wherein the calcium citrate malate exhibits one or more of: a pore area of at least about 30 m2/g; a dissolution rate of at least about 95% by weight of the calcium citrate malate in less than about 120 seconds.

Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

Abstract: The present invention relates to an economic process for preparing surface-reacted calcium carbonate. The present invention further relates to a surface-reacted calcium carbonate having an increased specific BET surface area, and the use of a process for adjusting the specific BET surface area.

Abstract: A method for treating in an industrial water treatment system for at least two of metal corrosion inhibition, scale inhibition, suspended matter dispersion, biocide efficacy, or biofilm removal/biofilm dispersion is taught by the use of at least one compound which is a salt derived from a thioamine or an oxyamine and an acid.

Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.

Abstract: The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.

Abstract: Methods for removing, or leaching, cobalt or other diamond-diamond bonding catalysts from polycrystalline diamond compacts (PDCs) or other structures formed from polycrystalline diamond include leaching under conditions that simulate use of PDCs in a hot hole drilling environment. A leaching agent may be formulated, when used under appropriate conditions, to remove or substantially remove cobalt or another catalyst from polycrystalline diamond without dissolving, degrading or otherwise attacking a substrate that supports or carries the polycrystalline diamond. The leaching agent may include one or more components that mimick the chemicals or conditions to which a PDC would be exposed in a hot hole drilling environment. Polycrystalline diamond structures from which cobalt or another diamond-diamond bonding catalyst has been removed or substantially removed are also disclosed, as are systems for leaching cobalt or other diamond-diamond bonding catalysts from polycrystalline diamond.

Abstract: Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium ions per milligram of the psychoactive substance. The therapeutically effective dose of lithium ions is administered using lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium aspartate, or analogs thereof using a delivery vehicle selected from pills, tablets, capsules, gelcaps, liquids, syrups, injectable liquids, powders, or foods and administered prior to, with, or after administration of the psychoactive substance. The psychoactive substance includes one or more of anandamide, 2-arachidonoyl glycerol, 2-arachidonoyl glycerol ether, tetrahydrocannabinol, cannabinol, cannabidiol, or analogs thereof and may be administered using the delivery vehicle.

Abstract: The present invention relates to an economic process for preparing surface-reacted calcium carbonate. The present invention further relates to a surface-reacted calcium carbonate having an increased specific BET surface area, and the use of a process for adjusting the specific BET surface area.

Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.

Abstract: Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.

Abstract: An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided.

Abstract: The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof.

Abstract: The invention provides a method for extracting a Staphylococcus aureus antigen which comprises using an extraction reagent with a pH of no higher than 5.0, containing one or more acids selected from among hydrochloric acid, acetic acid, citric acid, phosphoric acid, sulfuric acid and nitric acid, to extract a Staphylococcus aureus antigen comprising a methicillin-resistant Staphylococcus aureus antigen and/or a methicillin-sensitive Staphylococcus aureus antigen, from Staphylococcus aureus in a specimen. The invention further provides a method for assessing Staphylococcus aureus.

Abstract: The present invention provides a liquid pharmaceutical formulation comprising a therapeutic protein, a surfactant and at least an antioxidant selected from the group of radical scavengers, chelating agents or chain terminators.

Abstract: The invention relates to a process for producing pharmaceutically acceptable salts of fingolimod (I), comprising the step of reacting N-[1,1-bis hydroxymethyl-3-(4-octyl phenyl)-propyl]-acylamide (II) with an acidic compound. Furthermore, the invention provides different pharmaceutically acceptable salts of fingolimod and a polymorphic form of fingolimod hydrochloride.

Abstract: The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts.

Abstract: The invention relates to the use of radical traps in detergents and cleaners in order to improve cleaning performance, in particular for dirt containing polymerizable dyes.

Abstract: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

Abstract: The present application relates to dietary supplements, in particular, a horse calming supplement comprising a calcium coordinated compound.

Abstract: The present invention relates to pharmaceutical compositions suitable for inhalation, comprising as an active ingredient calcium lactate or calcium citrate. The invention also relates to methods of treating, preventing, and reducing the spread of an infection of the respiratory tract, comprising administering a pharmaceutical composition that comprises calcium lactate or calcium citrate as an active ingredient.

Abstract: A finished pharmaceutical product adapted for oral delivery of a physiologically active peptide agent, wherein the product comprises a therapeutically effective amount of the active peptide agent; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent, wherein the pH-lowering agent is present in the finished pharmaceutical product in a quantity which, if the product were added to 10 milliliters of 0.1M aqueous sodium bicarbonate solution, would be sufficient to lower the pH of the solution to no higher than 5.5, and wherein an outer surface of the product is substantially free of an acid-resistant protective vehicle. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic peptide active agent delivered orally.

Abstract: A method is disclosed for the recovery of an organic acid from a dilute salt solution in which the cation of the salt forms an insoluble carbonate salt. A tertiary amine and CO2 are introduced to the solution to form the insoluble carbonate salt and a complex between the acid and an amine. A water immiscible solvent, such as an alcohol, is added to extract the acid/amine complex from the dilute salt solution to a reaction phase. The reaction phase is continuously dried and a product between the acid and the solvent, such as an ester, is formed.

Abstract: A system and method for passive capture of ammonia in an enclosure containing material that gives off ammonia. The invention allows for the passage of gaseous NH3 through microporous hydrophobic gas-permeable membranes and its capture in a circulated acidic solution with concomitant production of a concentrated non-volatile ammonium salt.

Abstract: The invention relates to a method for producing a biodegradable molded part, comprising: providing a binding agent which contains a lyzable biopolymer; forming a molded part from the binding agent, wherein the time stability of the molded part to biological lysis is set by at least one of the following measures: adding a pulverized inorganic solid matter in a proportion of 5% to 85% of the mass of the binding agent before forming the molded part; thawing at least one of the surfaces of the molded part using a chemical or biological method such that the surface has a structuring in the range between 1 nm and 10 ?m. The invention further relates to an accordingly produced molded part.

Abstract: The invention relates to agents for treating and/or avoiding fire blight in plants of the Rosaceae, in particular of the subfamilies Maloideae and Rosoideae, containing formiates as the active component.

Abstract: The present invention provides crystalline and amorphous salts of O-desmethylvenlafaxine and processes for preparing said salts of O-desmethylvenlafaxine. The present invention further provides pharmaceutical compositions comprising said salts of O-desmethylvenlafaxine.

Abstract: The present invention is intended to provide a method for producing a liquid metal chelate compound which may be used as it is or diluted in water or the like, in a very simple procedure, in a short time, in a large quantity, and at a low cost, and to provide a metal chelate compound. A metal is ground in a liquid containing an organic acid to form an unoxidized fine metal powder. For example, a metal is ground in a liquid containing the organic acid, or the organic acid is added after the metal is ground in a liquid, or the organic acid is added while grinding the metal in a liquid. The unoxidized fine metal powder is oxidized in the liquid containing an organic acid to generate a metal ion. As a result of this, the unoxidized fine metal powder is chemically bonded to the organic acid in the liquid thereby producing a liquid metal chelate compound. The liquid metal chelate compound is adsorbed by an absorber.

Abstract: Hydroxycitric acid derivatives and salts thereof are provided which are useful as active ingredients of skin external preparations and cosmetics. Also provided are processes for production of the hydroxycitric acid derivatives, and skin external preparations and cosmetics containing the hydroxycitric acid derivatives. Specific hydroxycitric acid derivatives or salts thereof are produced wherein at least one of the hydroxyl groups of hydroxycitric acid or least one of the hydroxyl groups and at least one carboxyl group of hydroxycitric acid are modified to linkage moieties breakable by biological enzyme reaction. The hydroxycitric acid derivatives or salts thereof are added in skin external preparations and cosmetics.

Abstract: This invention relates to new double salts of (?)-hydroxycitric acid with group II metals. Preferred double salts are calcium and magnesium double salts of hydroxycitric acid of the formula II. This invention also includes a process for the preparation of these double salts by the addition of one metal compound from group II to (?)-hydroxycitric acid solution followed by the addition of other metal compound solution from group II. These double salts are tasteless and are soluble in water. They are useful as dietary supplements and in beverages.

Abstract: The present invention relates to high purity (?) Hydroxycitric acid metal salt derivatives of more than 98% purity having formula II (a-e), lla; X, 2X?Na Mb; X, 2X?K Hc; X?K, Y?Ca Hd1 X?Na, Y?Ca He; X=½Mg, Y?Mg and the method of preparation of high purity (?) hydroxycitric acid metal salt derivatives from (?) hydroxycitric acid lactone having formula (1) which in turn is isolated in a simple and efficient manner from dried rinds of the fruits of Garcinia species. This invention employs the HPLC method and optical rotation in assessing the purity (?) hydroxycitric acid and corresponding lactone (1).

Abstract: A substrate, such as a glass, glass ceramic, ceramic or metal substrate, is provided with a thermocatalytically active coating on at least a part of the substrate surface. The thermocatalytic coating contains an inorganic lithium salt or organic lithium-containing compound in an amount that is equivalent to not less than 2 wt. % of lithium ions, based on total coating weight. The thermocatalytic coating has a glass, glass solder or sol-gel matrix in which the lithium salt or organic lithium-containing compound is introduced. Optional barrier and IR-reflecting layers are arranged between the substrate surface and the thermocatalytically active coating.

Abstract: Processes are described for the production of an isolated medicinal composition for administration to mammals which comprises an effective amount of a free acid, salt or chelate of at least one naturally occurring form of an alpha hydroxyl organic acid comprising combining at least one naturally occurring form of an alpha hydroxy organic acid with an amount of base in an aqueous solution, wherein a total content of alpha hydroxyl organic acids amounts to between about 0.5% and about 35% w/w of the solution, for a time to hydrolyse substantially all forms of alpha hydroxyl organic acids present, neutralizing the solution to a pH between about 6.9 and about 7.6 to yield a free acid, salt or chelate of free acids of substantially all naturally occurring forms of alpha hydroxyl organic acids, and optionally lyophilizing the solution to produce an isolated medicinal composition. Compositions produced by these processes are disclosed and claimed.

Abstract: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

Abstract: Disclosed is a hydroxycitric acid salt composition comprising a mixture of calcium and potassium salts of hydroxycitric acid, preferably in a defined proportion. The HCA salts are prepared by a process that includes treating an aqueous extract of Garcinia cambogia or Garcinia indica fruit with a liquid quaternizing agent such as a trialkylamine in which the alkyl groups are octyl, caprylyl, isooctyl, lauryl or decyl. The process yields a very pure, stabilized mixed salt composition that is free of potentially toxic chemical residues, and is substantially tasteless for optimal use in a variety of foods, beverages and dietary supplements.

Abstract: By using protonic acids, diesters of dicarbonic acid may be stabilized against thermal and chemical decomposition over a relatively long period. Mixtures of diesters of dicarbonic acid and protonic acids are outstandingly suitable for preserving foods.

Abstract: Citric acid is separated from a fermentation broth containing gluconic acid by using an adsorbent comprising a water-insoluble, macroreticular or gel, strongly or weakly basic anionic exchange resin possessing quaternary or tertiary amine functional groups, said a anionic exchange resin having a cross-linked acrylic or styrene resin matrix and a desorbent comprising water or dilute sulfuric acid. The pH of the feed is maintained below the first ionization constant (pKa1) of citric acid to maintain selectivity.

Abstract: Disclosed are creatine salts having the general formula wherein A is a member of a group consisting of an anion of ketoglutaric acid and succinic acid.

Abstract: Citric acid is separated from a fermentation broth containing gluconic acid by using an adsorbent comprising a water-insoluble, macroreticular or gel, strongly or weakly basic anionic exchange resin possessing quaternary or tertiary amine functional groups, said a anionic exchange resin having a cross-linked acrylic or styrene resin matrix and a desorbent comprising water or dilute sulfuric acid. The pH of the feed is maintained below the first ionization constant (pKa1) of citric acid to maintain selectivity.

Abstract: A method for preparing, from at least one hygroscopic substance, mixtures that can be granulated and that have little hygroscopicity. The corresponding mixtures, especially carnitine-magnesium citrate and carnitine-magnesium hydroxycitrate, are produced.

Abstract: Described are tri-, tetra-, and penta-metal complex salts of hydroxycitric acid, compositions containing the same, and methods of making the same, where the salt comprises at least three different metals selected from zinc, magnesium, sodium, potassium, and calcium.

Abstract: A specific form of a dual mineral salt having potassium, magnesium, and citrate in a stoichiometric ratio of potassium:magnesium of less than 4:1 is disclosed. Methods of making the composition and using the composition as a dietary supplement are also disclosed.

Abstract: The invention is directed to the retention of the stability of formulations useful for a gene therapy during the preparation and preservation. In the invention, at least one saccharide and/or at least one non-hydrophobic amino acid and/or at least one organic acid having two or more carboxyl groups except amino acids, or a collagen or a gelatin and at least one amino acid are added to a gene formulation.

Abstract: The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R1 to R11 are as defined herein.